STATE OF COLORADO DEPARTMENT OF REGULATORY AGENCIES Colorado State Board of Pharmacy Approved Statewide Protocol for Prescribing Hormonal Contraceptive Patches and Oral Contraceptives

(Appendix A) This collaborative pharmacy practice statewide protocol authorizes qualified Colorado-licensed pharmacists ("Pharmacists") to perform t h e pertinent physical assessments and prescribe hormonal contraceptive patches and oral contraceptives under the conditions of this protocol and according to and in compliance with all applicable state and federal laws and rules. Definitions (1)

"Clinical visit" means a consultation with a healthcare provider, other than a pharmacist, for women's health, which should address contraception and age-appropriate screening.

(2)

"Hormonal contraceptive patch" means a transdermal patch applied to the skin of a patient, by the patient or by a practitioner, that releases a drug composed of a combination of hormones that is approved by the United States Food and Drug Administration to prevent pregnancy.

(3)

"Oral hormonal contraceptive" means a drug composed of a hormone or a combination of hormones that is approved by the United States Food and Drug Administration to prevent pregnancy and that the patient to whom the drug is prescribed may take orally.

Training Program Only a Colorado-licensed pharmacist, who has completed an Accreditation Council for Pharmacy Education (ACPE) accredited educational training program related to the prescribing of contraceptives by a pharmacist, may dispense hormonal contraceptive patches and oral hormonal contraceptives to a patient. In addition, pharmacists shall comply with the most current United States Medical Eligibility Criteria (USMEC) for Contraceptive Use as adopted by the U.S. Centers for Disease Control and Prevention (CDC). Age Requirements A pharmacist may prescribe hormonal contraceptive patches and self-administered oral hormonal contraceptives to a person who is at least 18 years of age.

Further Conditions (1)

For each new patient requesting a contraceptive service and, at a minimum of every twelve months for each returning patient, a participating pharmacist must: (a) (b) (c) (d) (e) (f) (g)

Obtain a completed Colorado Self-Screening Risk Assessment Questionnaire; Utilize and follow the Colorado Standard Procedures Algorithm to perform the patient assessment; Prescribe, if clinically appropriate, the hormonal contraceptive patch or self-administered oral hormonal contraceptive, or refer to a healthcare practitioner; Provide the patient with a Visit Summary; Advise the patient to consult with a primary care practitioner or women's health care practitioner; Refer any patient that may be subject to abuse to an appropriate social services agency; and Ensure that the pharmacy provides appropriate space to prevent the spread of infection and ensure confidentiality.

(2)

If the hormonal contraceptive patch or self-administered oral hormonal contraceptive is dispensed, it must be done as soon as practicable after the pharmacist issues the prescription and shall include any relevant educational materials.

(3)

A pharmacist must not: (a) (b) (c)

(4)

Require a patient to schedule an appointment with the pharmacist for the prescribing or dispensing of a hormonal contraceptive patch or self-administered oral hormonal contraceptive; Continue to prescribe and dispense a hormonal contraceptive to a patient beyond three years from the initial prescription without evidence of a clinical visit; or Prescribe in instances that the Colorado Standard Procedures Algorithm requires referral to a provider.

Records: (a)

Pursuant to Pharmacy Board Rule 17.00.50, a process shall be in place for the pharmacist to communicate with the patient’s primary care provider and document changes to the patient’s medical record. If the patient does not have a primary care provider, or is unable to provide contact information for his or her primary care provider, the pharmacist shall provide the patient with a written record of the drugs or devices furnished and advise the patient to consult an appropriate health care professional of the patient’s choice.

(b)

Pharmacists shall comply with all aspects of Pharmacy Board Rules 17.01.00 and 17.02.00 with respect to the maintenance of proper records.

STANDARD PROCEDURES ALGORITHM FOR COLORADO RPH PRESCRIBING OF CONTRACEPTIVES

Hormonal Contraceptive Self-Screening Questionnaire (form updated Nov16) Name__________________________ Health Care Provider’s Name ____________________ Date_________ Date of Birth_____________ Age*_______ Weight_______ Do you have health insurance? Yes / No What was the date of your last women’s health clinical visit? _____________________________________________ Any Allergies to Medications? Yes / No If yes, list them here: ____________________________________________

Background Information: 1 2 3

Do you think you might be pregnant now? What was the first day of your last menstrual period? Have you ever taken birth control pills, or used a birth control patch, ring, or injection? Have you previously had contraceptives prescribed to you by a pharmacist? Did you ever experience a bad reaction to using hormonal birth control? - If yes, what kind of reaction occurred? Are you currently using any method of birth control including pills, or a birth control patch, ring or shot/injection? - If yes, which one do you use? Have you ever been told by a medical professional not to take hormones? Do you smoke cigarettes?

4 5

Medical History: Have you given birth within 21 days? If yes, how long ago? 6 Are you currently breastfeeding? 7 Do you have diabetes? 8 Do you get migraine headaches? If so, have you ever had the kind of headaches that start with 9

Yes □ No□ ___/___/___ Yes □ No □ Yes □ No □ Yes □ No □ __________ Yes □ No □ __________ Yes □ No □ Yes □ No □ Yes □ Yes □ Yes □ Yes □

No □ No □ No □ No □

Do you have high blood pressure, hypertension, or high cholesterol? (Please indicate yes, even if it is controlled by medication) Have you ever had a heart attack or stroke, or been told you had any heart disease? Have you ever had a blood clot? Have you ever been told by a medical professional that you are at risk of developing a blood clot? Have you had recent major surgery or are you planning to have surgery in the next 4 weeks? Have you had bariatric surgery or stomach reduction surgery? Do you have or have you ever had breast cancer? Do you have or have you ever had hepatitis, liver disease, liver cancer, or gall bladder disease, or do you have jaundice (yellow skin or eyes)? Do you have lupus, rheumatoid arthritis, or any blood disorders? Do you take medication for seizures, tuberculosis (TB), fungal infections, or human immunodeficiency virus (HIV)? - If yes, list them here:

Yes □

No □

Yes □ Yes □ Yes □

No □ No □ No □

Yes □ Yes □ Yes □ Yes □

No □ No □ No □ No □

Yes □ Yes □

No □ No □

20

Do you have any other medical problems or take any medications, including herbs or supplements? - If yes, list them here:

Yes □

No □

21

Will you be immobile for a long period? (e.g. flying on a long airplane trip, etc.)

warning signs or symptoms, such as flashes of light, blind spots, or tingling in your hand or face that comes and goes completely away before the headache starts?

10 11 12 13 14 15 16 17 18 19

Do you have a preferred method of birth control that you would like to use? □ A pill you take each day □ A patch that you change weekly □ Other (ring, injectable, implant, or IUD) Internal use only verified DOB* with valid photo ID BP Reading _______/______ Pharmacist Name ____________________________ Pharmacist Signature ___________________________ Drug Prescribed_____________________ Rx# ______________ -or- Patient Referred-circle reason(s) Sig: _________________________(Pharmacy Phone ______________ Address _______________________ ) Notes: __________________________________________________________________________________

Summary Chart of U.S. Medical Eligibility Criteria for Contraceptive Use Pages 1,2 ..................Color coded in the left column to match the corresponding question of the Oregon Hormonal Contraception Self-Screening Tool Questionnaire. Pages 3,4 .............. Arranged alphabetically by disease state

Key: 1 2 3 4

No restriction (method can be used) Advantages generally outweigh theoretical or proven risks Theoretical or proven risks usually outweigh the advantages Unacceptable health risk (method not to be used)

Updated November 2016. This summary sheet only contains a subset of the recommendations from the US MEC. For complete guidance, see: http://www.cdc.gov/reproductivehealth/unintendedpregnancy/USMEC.htm

Corresponding to the order of the Colorado Hormonal Contraception Self Screening Tool Questionnaire: Condition

Sub-condition

Initiating Continuing Menarche to <40=1 >40=2

Age

Smoking

Pregnancy Postpartum (see also Breastfeeding)

Breastfeeding (see also Postpartum) Diabetes mellitus (DM)

Headaches

Hypertension

History of high blood pressure during pregnancy Hyperlipidemias Peripartum cardiomyopathy‡

Combined pill, patch, ring

a) Age < 35 b) Age > 35, < 15 cigarettes/day c) Age > 35, >15 cigarettes/day (Not Eligible for contraception) a) < 21 days b) 21 days to 42 days: (i) with other risk factors for VTE (ii) without other risk factors for VTE c) > 42 days a) < 1 month postpartum b) 1 month or more postpartum a) History of gestational DM only b) Non-vascular disease b) Other abnormalities: (i) non-insulin dependent (ii) insulin dependent‡ c) Nephropathy/ retinopathy/ neuropathy‡ d) Other vascular disease or diabetes of >20 years' duration‡ a) Non-migrainous b) Migraine: i) without aura, age <35 ii) without aura, age >35 iii) with aura, any age a) Adequately controlled hypertension b) Elevated blood pressure levels (properly taken measurements): (i) systolic 140-159 or diastolic 90-99 (ii) systolic ≥160 or diastolic ≥100‡ c) Vascular disease

a) Normal or mildly impaired cardiac function: (i) < 6 months (ii) > 6 months

Progestin-only pill

Other Contraception Options Indicated for Patient

2 3 4 NA* 4

3* 2

1 1

1 3* 2*

1 2* 1*

Yes Yes Yes

1

1

Yes

Yes Yes Yes Yes Yes Yes NA* Yes Yes Yes

2 2 3/4*

2 2 2

Yes Yes Yes

3/4*

2

Yes

1*

2*

1*

1*

Yes

2* 3* 4*

3* 4* 4*

1* 1* 2*

2* 2* 3* 1*

Yes Yes Yes Yes

3

1

Yes

4

2

Yes

4 2

2 1

Yes Yes

2/3*

2*

Yes

4 3

1 1

Sub-condition

Combined pill, patch, ring Initiating

Initiating Continuing Menarche to <18=1 18-45=1 >45=1 1 1 1 NA* 1

3*

Condition

Yes Yes

b) Moderately or severely impaired cardiac function Multiple risk (such as older age, smoking, factors for arterial diabetes and hypertension) cardiovascular disease Ischemic heart Current and history of disease‡ Valvular heart a) Uncomplicated disease b) Complicated‡ Stroke‡ History of cerebrovascular accident Thrombogenic mutations‡ Deep venous a) History of DVT/PE, not on thrombosis anticoagulant therapy (DVT) /Pulmonary i) higher risk for recurrent embolism (PE) DVT/PE ii) lower risk for recurrent DVT/PE b) Acute DVT/PE c) DVT/PE and established on anticoagulant therapy for at least 3 months i) higher risk for recurrent DVT/PE ii) lower risk for recurrent DVT/PE d) Family history (first-degree relatives) e) Major surgery (i) with prolonged immobilization (ii) without prolonged immobilization f) Minor surgery without immobilization History of a) Restrictive procedures bariatric surgery‡ b) Malabsorptive procedures Breast disease/ Breast Cancer

a) Undiagnosed mass b) Benign breast disease c) Family history of cancer d) Breast cancer:‡ i) current ii) past and no evidence of current disease for 5 years

Continuing

Progestin-only pill

Initiating

Other Contraception Options Indicated for Patient

Continuing

4

2

Yes

3/4*

2*

Yes

4 2 4 4

2

3

Yes

3

Yes Yes Yes

1 1 2

4*

2*

Yes

4

2

Yes

3

2

Yes

4

2

Yes

4*

2

Yes

3*

2

Yes

2

1

Yes

4

2

Yes

2

1

Yes

1

1

Yes

1

1

Yes

COCs: 3

3

Yes

2* 1 1

2* 1 1

Yes Yes Yes

4

4

Yes

3

3

Yes

Condition

Viral hepatitis Cirrhosis Liver tumors

Gallbladder disease

History of Cholestasis Systemic lupus erythematosus‡

Rheumatoid arthritis

Sub-condition

Combined pill, patch, ring Initiating 3/4* 1

Continuing 2 1

Progestin-only pill

Initiating

Other Contraception Options Indicated for Patient

Continuing

1 4

1 1 1 3

Yes Yes Yes Yes

2 4 4

2 3 3

Yes Yes Yes

2 3 3 2 2 3 4

2 2 2 2 1 2 3

Yes Yes Yes Yes Yes Yes Yes

2 2 2 2 2

2 2 2 1 1

Yes Yes Yes Yes Yes

(see also Drug Interactions) a) Non-pelvic b) Pelvic

1* 1* 1*

1* 1* 1*

Yes Yes Yes

High risk HIV infected (see also Drug Interactions)‡ AIDS (see also Drug Interactions) ‡ Clinically well on therapy a) Nucleoside reverse transcriptase inhibitors b) Non-nucleoside reverse transcriptase inhibitors c) Ritonavir-boosted protease inhibitors a) Certain anticonvulsants (phenytoin, carbamazepine, barbiturates, primidone, topiramate, oxcarbazepine) b) Lamotrigine a) Broad spectrum antibiotics b) Antifungals c) Antiparasitics d) Rifampicin or rifabutin therapy

1 1*

1 1*

Yes Yes

1*

1*

Yes

a) Acute or flare b) Carrier/Chronic a) Mild (compensated) b) Severe‡ (decompensated) a) Benign: i) Focal nodular hyperplasia ii) Hepatocellular adenoma‡ b) Malignant‡ a) Symptomatic: (i) treated by cholecystectomy (ii) medically treated (iii) current b) Asymptomatic a) Pregnancy-related b) Past COC-related a) Positive (or unknown) antiphospholipid antibodies b) Severe thrombocytopenia c) Immunosuppressive treatment d) None of the above a) On immunosuppressive therapy b) Not on immunosuppressive therapy

Blood Conditions?

Epilepsy‡ Tuberculosis‡ (see also Drug Interactions) HIV

Antiretroviral therapy

Anticonvulsant therapy

Antimicrobial therapy

1*

If on treatment, see Drug Interactions. 1

Yes

2*

2*

Yes

3*

3*

Yes

3*

3*

Yes

3* 1 1 1 3*

1 1 1 1 3*

Yes Yes Yes Yes Yes

Alphabetical Listing of USMEC Contraceptive Eligibility By Disease State 2

2

Yes

Combined pill, patch, ring

Progestin-only pill

Other Contraception Options Indicated for Patient

b) Asymptomatic Condition

Sub-condition

Combined pill, patch, ring

Initiating Breast disease/ Breast Cancer

a) Undiagnosed mass b) Benign breast disease c) Family history of cancer d) Breast cancer‡ i) current ii) past and no evidence of current disease for 5 years a) < 1 month postpartum b) 1 month or more postpartum

Breastfeeding (see also Postpartum) Cervical cancer Awaiting treatment Cervical ectropion Cervical intraepithelial neoplasia Cirrhosis a) Mild (compensated) b) Severe‡ (decompensated) Cystic Fibrosis Deep venous a) History of DVT/PE, not on thrombosis anticoagulant therapy (DVT) i) higher risk for recurrent /Pulmonary DVT/PE embolism (PE) ii) lower risk for recurrent DVT/PE b) Acute DVT/PE c) DVT/PE and established on anticoagulant therapy for at least 3 months i) higher risk for recurrent DVT/PE ii) lower risk for recurrent DVT/PE d) Family history (first-degree relatives) e) Major surgery (i) with prolonged immobilization (ii) without prolonged immobilization f) Minor surgery without immobilization Depressive disorders Diabetes mellitus a) History of gestational DM only (DM) b) Non-vascular disease Diabetes mellitus (i) non-insulin dependent (cont.) (ii) insulin dependent‡ c) Nephropathy/ retinopathy/ neuropathy‡ d) Other vascular disease or diabetes of >20 years' duration‡ Endometrial cancer‡ Endometrial hyperplasia Endometriosis Epilepsy‡ (see also Drug Interactions) Gallbladder a) Symptomatic disease (i) treated by cholecystectomy (ii) medically treated (iii) current

Continuing

Progestin-only pill

Initiating

Other Contraception Options Indicated for Patient

Sub-condition

Continuing 2*

Yes

1 1

1 1

Yes Yes

Gestational trophoblastic disease

4 3

4 3

Yes Yes

Headaches

3* 2*

2* 1*

Yes Yes

2 1 2

1 1 1

Yes Yes Yes

1 4 1*

1 3 1*

Yes Yes Yes

4

2

Yes

3

2

Yes

4

2

Yes

4*

2

Yes

3*

2

Yes

2

1

Yes

4

2

Yes

2

1

Yes

1

1

Yes

1*

1*

Yes

1

1

Yes

2 2 3/4*

2 2 2

Yes Yes Yes

3/4*

2

Yes

1

1

Yes

1

1

Yes

1 1*

1 1*

Yes Yes

Ovarian cancer‡ Parity

2 3 3

2 2 2

Yes Yes Yes

Past ectopic pregnancy

2*

Initiating

History of bariatric surgery‡

a) Decreasing or undetectable ß-hCG levels b) Persistently elevated ß-hCG levels or malignant disease‡ a) Non-migrainous b) Migraine i) without aura, age <35 ii) without aura, age >35 iii) with aura, any age a) Restrictive procedures b) Malabsorptive procedures

History of a) Pregnancy-related cholestasis b) Past COC-related History of high blood pressure during pregnancy History of pelvic surgery HIV

Hyperlipidemias Hypertension

Inflammatory bowel disease Ischemic heart disease‡ Liver tumors

Malaria Multiple risk factors for arterial cardiovascular disease Obesity

High risk HIV infected (see also Drug Interactions)‡ AIDS (see also Drug Interactions) ‡ Clinically well on therapy a) Adequately controlled hypertension b) Elevated blood pressure levels (properly taken measurements) (i) systolic 140-159 or diastolic 90-99 (ii) systolic ≥160 or diastolic ≥100‡ c) Vascular disease (Ulcerative colitis, Crohn’s disease) Current and history of a) Benign i) Focal nodular hyperplasia ii) Hepatocellular adenoma‡ b) Malignant‡ (such as older age, smoking, diabetes and hypertension)

a) >30 kg/m2 body mass index (BMI) b) Menarche to < 18 years and > 30 kg/m2 BMI a) Nulliparous b) Parous

Continuing

Continuing

Initiating

1

1

Yes

1

1

Yes

1*

2*

1*

1*

Yes

2* 3* 4*

3* 4* 4*

1* 1* 2*

2* 2* 3*

1 COCs: 3 P/R: 1 2 3 2

1 3

Yes Yes Yes Yes Yes

1 2 1

Yes Yes Yes

1

1

Yes

1 1*

1 1*

Yes Yes

1*

1*

Yes

2/3* 3*

If on treatment, see Drug Interactions. 2* 1*

Yes Yes

3

1

Yes

4

2

Yes

4 2/3*

2 2

Yes Yes

4

2

3

Yes

2 4 4 1 3/4*

2 3 3 1 2*

Yes Yes Yes Yes Yes

2

1

Yes

2

1

Yes

1 1 1 1

1 1 1 2

Yes Yes Yes Yes

Alphabetical Listing of USMEC Contraceptive Eligibility By Disease State Condition

Sub-condition

Combined pill, patch, ring Initiating

Pelvic inflammatory disease

a) Past, (assuming no current risk factors of STIs) (i) with subsequent pregnancy (ii) without subsequent pregnancy b) Current Peripartum a) Normal or mildly impaired cardiomyopathy‡ cardiac function (i) < 6 months (ii) > 6 months b) Moderately or severely impaired cardiac function Postabortion a) First trimester b) Second trimester c) Immediately post-septic abortion Postpartum a) < 21 days (see also b) 21 days to 42 days Breastfeeding) (i) with other risk factors for VTE (ii) without other risk factors for VTE c) > 42 days Postpartum (in a) < 10 minutes after delivery of breastfeeding or the placenta non-breastfeeding b) 10 minutes after delivery of the women, including placenta to < 4 weeks post-cesarean c) > 4 weeks section) d) Puerperal sepsis Pregnancy Rheumatoid a) On immunosuppressive arthritis therapy b) Not on immunosuppressive therapy Schistosomiasis a) Uncomplicated b) Fibrosis of the liver‡ Severe dysmenorrhea Sexually a) Current purulent cervicitis or transmitted chlamydial infection or gonorrhea infections (STIs) b) Other STIs (excluding HIV and hepatitis) Sexually c) Vaginitis (including transmitted trichomonas vaginalis and infections bacterial vaginosis) (cont.) d) Increased risk of STIs Smoking a) Age < 35 b) Age > 35, < 15 cigarettes/day c) Age > 35, >15 cigarettes/day Solid organ a) Complicated transplantation‡ b) Uncomplicated Stroke‡ History of cerebrovascular accident Superficial a) Varicose veins venous b) Superficial thrombophlebitis thrombosis Systemic lupus erythematosus‡

Thrombogenic mutations‡

a) Positive (or unknown) antiphospholipid antibodies b) Severe thrombocytopenia c) Immunosuppressive treatment d) None of the above

Continuing

Progestin-only pill Initiating

Other Contraception Options Indicated for Patient

Sub-condition

Continuing

1 1

Yes Yes

1

1

Yes

4 3 4

1 1 2

Yes Yes Yes

1* 1* 1*

1* 1* 1*

Yes Yes Yes

1

Yes

3* 2

1 1

1

1

Yes Yes Yes

NA* 2

NA* 1

NA* Yes

2

1

Yes

1 1 1

1 1 1

Yes Yes Yes

1

1

Yes

1

1

Yes

1

1

Yes

1 2 3 4 4 2* 4

1 1 1 1 2 2

Yes Yes Yes Yes Yes Yes Yes

2

3

Combined pill, patch, ring Initiating

1 1

4

Condition

1 2

1 1

Yes Yes

4

3

Yes

2 2 2 4*

2 2 2 2*

Yes Yes Yes Yes

Thyroid disorders Simple goiter/ hyperthyroid/hypothyroid. Tuberculosis‡ a) Non-pelvic (see also Drug Interactions) b) Pelvic Unexplained (suspicious for serious condition) vaginal bleeding before evaluation Uterine fibroids Valvular heart a) Uncomplicated disease b) Complicated‡ Vaginal a) Irregular pattern without bleeding heavy bleeding patterns b) Heavy or prolonged bleeding Viral hepatitis a) Acute or flare b) Carrier/Chronic Antiretroviral Fosamprenavir (FPV) therapy (All other ARVs are 1 or 2 for all methods) Anticonvulsant a) Certain anticonvulsants therapy (phenytoin, carbamazepine, barbiturates, primidone, topiramate, oxcarbazepine) b) Lamotrigine Antimicrobial a) Broad spectrum antibiotics therapy b) Antifungals c) Antiparasitics d) Rifampicin or rifabutin therapy SSRIs St. John’s Wort

Continuing

Progestin-only pill Initiating

Other Contraception Options Indicated for Patient

Continuing

1

1

Yes

1*

1*

Yes

1* 2*

1* 2*

Yes Yes

1 2

1 1

Yes Yes

4 1

1 2

Yes Yes

2* 1

3*

1 2*

Yes Yes Yes Yes

3*

3*

Yes

3* 1 1 1 3*

1 1 1 1 3*

Yes Yes Yes Yes Yes

1

1

Yes

1* 3/4* 1

2 1

2 2 I = initiation of contraceptive method; C = continuation of contraceptive method; NA = Not applicable * Please see the complete guidance for a clarification to this classification: www.cdc.gov/reproductivehealth/unintendedpregnancy/USMEC.htm ‡ Condition that exposes a woman to increased risk as a result of unintended pregnancy.

Yes

Rule 17 Appendix A.pdf

Loading… Page 1. Whoops! There was a problem loading more pages. Retrying... Rule 17 Appendix A.pdf. Rule 17 Appendix A.pdf. Open. Extract. Open with. Sign In. Main menu.

1MB Sizes 2 Downloads 132 Views

Recommend Documents

Rule 17 Appendix B.pdf
Page 1 of 5. STATE OF COLORADO. DEPARTMENT OF REGULATORY AGENCIES. Colorado State Board of Pharmacy Approved Statewide. Protocol for ...

Rule 17 Appendix B.pdf
Lozenge. • Nicotine lozenges are available in 2-mg and 4-mg (per piece) doses. The 2-mg. lozenge is recommended for patients who smoke their first cigarette ...

Rule 17 Appendix A.pdf
Page 1 of 8. STATE OF COLORADO. DEPARTMENT OF REGULATORY AGENCIES. Colorado State Board of Pharmacy Approved Statewide Protocol for ...

17 5.4 APPENDIX 4 DATA TYPES AND SCALING FACTORS.pdf ...
2_2_1 GERD Financed by Abroad Total domestic intramural expenditure on R&D during a given period as. a percentage of GDP. Intramural R&D expenditure is all expenditure for. R&D performed within a statistical unit or sector of the economy during a. sp

Amendment to sub rule 17 of rule 10 vide GO.NO.39 dt ... - aptgguntur
School Education – The Andhra Pradesh Educational Institutions (Establishment, ... taken up, the competent authority may transfer the staff, with or without posts ...

Amendment to sub rule 17 of rule 10 vide GO.NO.39 dt ... - aptgguntur
School Education – The Andhra Pradesh Educational Institutions (Establishment, ... 1 G.O.Ms.No.1, Education (PS.2) Department, dated 01.01.1994. 2 From the ...

Z'17 Rule Book Final Edition.pdf
Z'17 Rule Book Final Edition.pdf. Z'17 Rule Book Final Edition.pdf. Open. Extract. Open with. Sign In. Main menu. Displaying Z'17 Rule Book Final Edition.pdf.

Rule
1 Oct 2017 - in which everyday life activities take place, and is related to the patient's physical disorder. Orthotics and ... canes, commodes, traction equipment, suction machines, patient lifts, weight scales, and other items ...... (iii) Elevator

Rule
Oct 1, 2017 - (8) BUREAU OF TENNCARE (BUREAU) shall mean the administrative unit of TennCare which is responsible for ..... (75) LONG-TERM CARE shall mean programs and services described under Rule 1200-13-01- .01. (76) MCC ...... tional or technical

Rule
Oct 1, 2017 - nance and Administration to provide TennCare-covered benefits to eligible enrollees in the. TennCare Medicaid and ..... fied psychiatrist or a person with at least a Master's degree and/or clinical training in an ac- cepted mental .....

Rule
Oct 1, 2017 - (26) CONTRACTOR shall mean an organization approved by the Tennessee Department of. Finance and Administration to provide TennCare-covered benefits to eligible enrollees in the. TennCare Medicaid and TennCare Standard programs. (27) CON

Rule
Oct 1, 2017 - U.S. Department of Justice, Drug Enforcement Administration or by the ...... TennCare shall not cover drugs considered by the FDA to be Less ...

Online Appendix
Aug 13, 2013 - Online Appendix Figures 3a-4e present further evidence from the survey .... Control variables include age, gender, occupation, education, and ...

Online Appendix
Aug 13, 2013 - Online Appendix Figures 3a-4e present further evidence from the survey responses on the .... Notes: Data from a survey of 70 individuals in 9 villages. ...... You will stay in the assigned room for 20 minutes listening to a.

Online Appendix
Length of business registration in days. 2. Land access sub-score ..... Trends. Province trends. Cluster. Commune. Commune. Commune. Commune. Province.

APPENDIX 12
Certain LFAs, nominated as Dedicated User Areas (DUA), are allocated for special use (such as concentrated helicopter training) and are managed under local ...

Online Appendix
Power Capital Variables adds up all ranking positions by terms (excluding the above top 4 positions). 2 ever held by native officials connected to a commune (in.

Web Appendix
We again assume U(x)=x throughout, following Doyle. As in our paper and in. Bleichrodt, Rohde, and Wakker (2009; BRW henceforth), we write ln for the natural logarithm instead of Doyle's log. As in the main text, (T:F) denotes receiving $F>0 at time

Web Appendix
We again assume U(x)=x throughout, following Doyle. As in our paper and in. Bleichrodt, Rohde, and Wakker (2009; BRW henceforth), we write ln for the natural.

Online Appendix
When γ = 1, Equation 3 becomes α(p – c) = 1 + exp(δ – αp). The left-hand ... We averaged daily five-year maturity credit default swap (CDS) spreads on GM debt.

APPENDIX for LABORATORY 3 SHEET APPENDIX A
An Interrupt Service Routine (ISR) or Interrupt Handler is a piece of code that should be executed when an interrupt is triggered. Usually each enabled interrupt has its own ISR. In. AVR assembly language each ISR MUST end with the RETI instruction w

Appendix - Shuchita Prakashan
2012 - Dec [5] (a) Superb Electronics Ltd. is a manufacturer of electronic transformers, semi-conductor devices and other electrical and electronic equipments. During the course of such manufacture, the assessee also manufactured machinery in the nat

Online Appendix
War Draw. 0.006. 0.077. 0. 1. Civil War. 0.109. 0.312. 0. 1. Wealth (unlogged) ..... Sri Lanka. 1968. 2004. 0.405. 0.725. 3. 0.568. 0.835. 3. Sudan. 1968. 2004.

appendix
Mar 28, 2009 - TimE OF ExAmiNATiON. Vocational Subjects. 10.00 am to 12.45 pm [IST] including 15 minutes cool off time ... Physics/Geography/Accountancy.